Transdominant mutant Rev gene therapy
Latest Information Update: 30 Apr 2007
At a glance
- Originator Genetic Therapy; Novartis; University of Michigan
- Class Antivirals; Gene therapies
- Mechanism of Action Rev gene product inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections